Deals
Sanofi, Merck Said to Consider Exiting Vaccine Joint Venture
- Venture had sales of about $330 million in first half of 2015
- European venture sells flu, shingles, cervical cancer shots
This article is for subscribers only.
Sanofi and Merck & Co. are considering ending a two-decade-long joint venture to sell vaccines in Europe, as revenue from the products declines and Sanofi Chief Executive Officer Olivier Brandicourt reorganizes the French drugmaker’s operations, according to people familiar with the situation.
Brandicourt is reviewing the alliance because of a lack of promising assets in the business’s pipeline, said the people, who asked not to be identified because the deliberations are private. Unraveling the venture, in which Merck and Sanofi each hold half, would be complex and may hit snags along the way, one person said.